U.S. markets close in 37 minutes

Agile Therapeutics, Inc. (AGRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9900+0.1900 (+10.56%)
As of 03:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.8000
Bid1.9400 x 3100
Ask1.9900 x 900
Day's Range1.7600 - 2.0050
52 Week Range1.6500 - 16.0000
Avg. Volume49,007
Market Cap3.834M
Beta (5Y Monthly)1.13
PE Ratio (TTM)0.01
EPS (TTM)141.0400
Earnings DateNov 06, 2023 - Nov 10, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est250.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for AGRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Agile Therapeutics, Inc.
    Analyst Report: Merck & Co., Inc.Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, close to 40% of the firm's sales are generated in the United States.
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
  • GlobeNewswire

    Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    PRINCETON, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Chairperson and Chief Executive Officer Al Altomari and Chief Commercial Officer Amy Welsh will present at the H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY. Details on the Company presentation are as follows: Event: H.C. Wainwright 25th Annual Global Investment Conference Date: Wednesday, Sep


    Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter

    On August 9, Agile Therapeutics (NASDAQ:AGRX) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, Twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses.

  • Insider Monkey

    Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript

    Agile Therapeutics, Inc. (NASDAQ:AGRX) Q2 2023 Earnings Call Transcript August 9, 2023 Agile Therapeutics, Inc. beats earnings expectations. Reported EPS is $-3.1, expectations were $-3.48. Operator: Good morning, and welcome to the Agile Therapeutics Second Quarter of 2023 Financial Results Conference Call. Please note today’s event is being recorded. I would now like to turn […]